THE WOODLANDS, Texas--(BUSINESS WIRE)--In a continuation of its rapid growth, MolecularHealth announced the hiring of four new members of its marketing and sales team. The group brings decades of experience in product marketing, reimbursement strategy, business development and sales, all with a focus on oncology and diagnostics. MolecularHealth is working towards the launch of TreatmentMAP™, its cancer treatment decision support offering, in the first quarter of this year.
Dana Dilbeck joins the commercial/marketing group, led by Chief Commercial Officer Laura Housman, as vice president, market access and strategy. With over 18 years of experience in oncology payer and reimbursement strategies, Dilbeck will oversee U.S. market access and strategy for TreatmentMAP. Prior to joining MolecularHealth, she spent 15 years at U.S. Oncology, where she focused on the development and execution of the company’s successful managed care and Medicare strategies for a national network of over 1,000 community oncologists.
Mridula Iyer, Ph.D., has more than 10 years of experience in diagnostic services and joins the commercial/marketing group as director, product marketing. Iyer will oversee U.S. product marketing initiatives for TreatmentMAP. Iyer spent eight years at Qiagen, where she was instrumental in positioning the company’s complete portfolio of diagnostic and pharmaceutical products.
Daniel Helle joins the business development team, led by Chief Development Officer Chet Dye, as regional vice president, business development. Helle will lead Eastern U.S. business development efforts for TreatmentMAP. He comes to MolecularHealth with over 25 years of cancer diagnostic experience, focused in healthcare sales and sales management. Previously, he served as a regional manager for Clarient/GE, and was also part of the successful growth of Impath Inc. and US Labs.
Kregg Everett has more than 20 years of sales and management experience and also joins the business development team as regional vice president, business development. Everett will lead the Western U.S. business development efforts for TreatmentMAP. His previous experience was primarily focused in cancer diagnostic lab services, including serving as a regional director for Clarient/GE, covering much of the central U.S.
“With strong executive leadership in place, we are now working to build out our sales and marketing team with a group of professionals who have experience in bringing oncology and diagnostics products and offerings to market,” said Dye. “Laura and I believe that these individuals bring unique talents, as well as passion and commitment to deliver the best services possible for oncologists, pathologists and patients. They will each be instrumental in introducing MolecularHealth and TreatmentMAP to the oncology community.”
ABOUT MOLECULARHEALTH
MolecularHealth delivers on the promise of personalized, precision medicine. By using advanced proprietary information technologies to sift through terabytes of genetic and molecular test findings in a fraction of the time needed for current manual analysis, MolecularHealth provides doctors and patients with faster, more accurate insights into the role genes play in the progression and treatment of an individual’s cancer. MolecularHealth’s team of doctors, scientists, IT and business experts—including founders and executives of LION Bioscience, US Oncology and Novartis—works in partnership with some of the world’s leading healthcare and information technology companies, including the University of Texas MD Anderson Cancer Center, SAP AG, and the U.S. Food and Drug Administration (FDA). The company has locations in The Woodlands, Texas, Boston, Mass. and Heidelberg, Germany. Visit www.molecularhealth.com for more information and follow us on Twitter at www.twitter.com/molecularhealth.
